An extension study for seven patients in Japan with neuromyelitis optica spectrum disorder who completed the open-label period of study CD-IA-MEDI-551-1155 of Inebilizumab
Phase 3
- Conditions
- euromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
- Registration Number
- JPRN-jRCT2051210017
- Lead Sponsor
- Sato Toshiyuki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 7
Inclusion Criteria
Has completed at least 2 years in the OLP of Study CD-IA-MEDI-551-1155, and has not discontinued inebilizumab treatment in that study
Is deemed eligible to continue receiving inebilizumab by the Investigator
Exclusion Criteria
Has any condition that, in the opinion of the Investigator, would place the patient at unacceptable risk of complications, interfere with evaluation of inebilizumab or confound the interpretation of patient safety or study results
Lactating or pregnant females, or females who intend to become pregnant after signing the informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method